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ABSTRACT
Background    Reportedly, the recently established post-
operative adjuvant chemotherapies (ADJs) with tegafur 
and uracil (UFT) or fluoropyrimidine S (S-1) show bet-
ter survival than surgery alone in patients with advanced 
gastric cancer (GC). We analyzed chronological changes 
in postoperative prognosis of patients with advanced GC 
in our institute, and investigated the efficacy of ADJ in 
patients with stage II–III GC. 
Methods    Of 143 patients with stage II–III GC who 
underwent curative gastrectomy at Tottori University 
Hospital between 1998 and 2008, three died with opera-
tive complications within 1 month after surgery. The 
remaining 140 patients were followed to the end of 2013. 
We compared disease-free survival (DFS) and clinico-
pathological differences between 82 patients who under-
went gastrectomy during 1998–2002 (Group A) and 58 
patients who underwent gastrectomy during 2003–2008 
(Group B).  
Results    Operative quality, as represented by number 
of dissected lymph nodes, was similar in both groups, 
but the recurrence rate of Group A (51.2%) was higher 
than in Group B (37.9%, P = 0.12) and the 5-year DFS 
rate of Group B (62.3%) was higher than that of Group 
A (50.2%, P = 0.095). In stage II, the 5-year DFS rate 
of patients in Group B (73.3%) was similar to Group 
A (77%), but at tumor stage III, the 5-year DFS rate of 
patients in Group B increased to 48.7%, compared with 
33.1% of Group A. Between 2003 and 2008, S-1 was 
widely used as ADJ for stage II–III GC.
Conclusion    Postoperative ADJ with S-1 improved 
DFS of patients with stage III gastric cancer.
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Gastric cancer (GC) is the fourth most common ma-
lignancy worldwide1 and the second leading cause of 
cancer-related death, with the highest mortality rates 
reported in East Asia including Japan, Korea and China; 
approximately 60% of gastric cancers in the world are 
diagnosed in this area.2 Early detection and curative sur-
gery can improve survival of loco-regional GC but the 
survival rates of advanced or recurrent GC remain low. 
 Surgery is the main modality for the treatment of 
resectable GC. Surgical technique is the most important 
factor for patients’ outcome and has progressed rapidly 
in recent years with newly developed operative appa-
ratus. Furthermore, tegafur and uracil (UFT) and its 
derived anticancer drug, fluoropyrimidine S (S-1) report-
edly to have survival benefits for patients with curatively 
operated advanced GC as adjuvant chemotherapy (ADJ), 
as shown in large randomized studies in Japan.3, 4 Thus, 
from 2007, fluoropyrimidine-based therapy has been 
used as standard ADJ for stage II–III GC.5 
 However, the improvement of GC patients’ survival 
from single institutions has not been widely discussed. 
In the present study, we selected patients with stage II–
III GC who were treated over an 11-year period (1998–
2008) and we followed these patients at least 5 years. 
We divided these patients into two sub-groups (Group 
A, who were treated between 1998 and 2002; and Group 
B, who were treated between 2003 and 2008) and com-
pared clinicopathological characteristics and prognoses 
between the two groups.
MATERIALS AND METHODS
Patients
Between 1998 and 2008, 143 patients with stage II–III 
GC underwent curative gastrectomy with D2 or more 
extensive lymph node dissection for adenocarcinoma of 
the stomach. Three patients died with operative com-
plications within 1 month after surgery. We excluded 
these three patients and we enrolled the remaining 140 
patients for this study. All 140 patients (average age: 
62.7 years; range 34–89 years) had pathological stage 
II–III gastric adenocarcinomas.6 Clinicopathological 
characteristics of the patients were described according 
with the Japanese Classification of Gastric Carcinoma.6 
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All patients provided informed consent for the treatment 
including ADJ. The study design was approved by the 
Ethics Review Board of Tottori University. We divided 
the patients into two sub-groups (Group A, who were 
treated between 1998 and 2002; and Group B, who were 
treated between 2003 and 2008). All patients were fol-
lowed at our hospital or at our affi liated hospital till the 
end of 2013.
 
ADJ
DFS was defi ned as the time from the date of registra-
tion to the date of detection of progressive disease, 
death, or treatment discontinuation. The recurrence sites 
were detected by clinical fi ndings, enhanced computed 
tomography (CT), or magnetic resonance imaging (MRI). 
Between 1998 and 2008, ADJ was applied to 36 patients 
(40%) of Group A, and 34 patients (24%) of Group B. Of 
Group A patients, 30 (21.4%) received UFT and 6 (4.9%), 
S-1. While in Group B, 5 patients (3.6%) were treated 
with UFT and 29 patients (20.7%), S-1. Before 2001, 
UFT (300–600 mg/day) was mainly used; UFT-based 
ADJ was applied for a total of 35 patients. By 2002, S-1 
began to be used as ADJ for advanced GC; S-1 (80 mg/
m2) was given for a total of 35 patients. A summary of 
ADJ is listed in Table 1.
Table 1. Patients’ characteristics 
Group A Group B P value
n 82 58
Age (mean, SD) 67.5 (11.4) 66.9 (12) 0.934
Sex (male/female) 58/24 36/22 0.282
Histological type (well differen-
tiated/poorly differentiated) 51/31 27/31 0.301
Tumor stage (II/III) 32/50 32/26 0.059
Gastrectomy (Total/proximal/
distal) 46/1/35 25/3/30 0.166
Dissected number of lymph 
nodes (mean, SD) 35.5 (19.5) 38.9 (18.1) 0.156
Adjuvant chemotherapy (yes/no) 36/46 34/24 0.086
Chemotherapy (UFT-based/S-1) 30/6 5/29 < 0.001
Recurrence (yes/no) 42/40 22/36 0.12
Group A patients underwent gastrectomies during 1998–2002 and 
Group B patients, during 2003–2008. UFT, tegafur and uracil.
Statistical analysis
The terminology used in this study conforms to the Jap-
anese Classifi cation of Gastric Carcinoma, 3rd English 
edition.6 Differences between two parameters were com-
pared using the chi-squair test for independence, Fisher’s 
exact probability test, and the Mann-Whitney U test. 
Disease-free survival (DFS) was defi ned as time from 
date of registration to date of detection of progressive 
disease, death, or treatment discontinuation. Survival 
curves were estimated using the Kaplan-Meier method, 
and differences were analyzed using the stratifi ed log-
rank test. P value < 0.05 was regarded as statistically 
signifi cant.  
RESULTS
Table 1 shows the clinicopathological differences be-
tween Group A (82 patients who were treated between 
1998 and 2002) and Group B (58 patients who were 
treated between 2003 and 2008). Patients in Group A 
tended to be at more advanced stages, although not sig-
nifi cantly different. However, operative quality (number 
of dissected lymph nodes) did not differ between the 
groups. ADJ was administered to a larger percentage of 
Group B patients. The main ADJs for patients in Group 
A were UFT-based, but S-1 was the main adjuvant drug 
in Group B. 
 The recurrence rate of Group A (51.2%) was higher 
than that of Group B (37.9%, P = 0.12). Major sites of 
metastases were the lymph node in 14.6%/15.5% (Group 
A/B) patients, peritoneum in 23.1%/12.0% patients, liver 
in 7.3%/10.3% patients, lung in 4.8/3.9% patients and 
others in 4.8%/3.4% patients. Sites of metastases are 
summarized in Table 2. The 5-year DFS rate of Group 
A (50.2%) was lower than that of Group B (62.3%, P = 
0.095, Fig. 1), but not signifi cantly different for both re-
currence and DFS. 
Table 2. Sites of metastasis
Group A Group B P value
Metastatic sites 0.665
     Lymph nodes 12 9
     Peritoneum 19 7
     Liver 6 6
     Lung 4 2
     Others 4 2
Recurrence (yes/no) 42/40 22/36 0.12
 We also analyzed the survival effect of ADJ for 
these 140 patients. The 5-year DFS rate of 70 patients 
who received ADJ (54%) was close to that of 70 patients 
without ADJ (57%, P = 0.904). The 5-year DFS of the 35 
patients treated with S-1 (62.2%) was better than that of 
35 patients treated with UFT-based chemotherapy (45%) 
but not signifi cantly different (P = 0.208). For patients 
with stage III disease, 5-year DFS of 22 patients treated 
with UFT-based ADJ (30.3%) was close to that of 36 
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patients without chemotherapy, but increased to 46.6% 
in 18 patients treated with S-1. This difference was not 
signifi cant (P = 0.654). 
 
Subgroup analysis 
DFS rates in eligible patients were analyzed according to 
the disease stage (Japanese Classifi cation, 14th edition) 
and histological type. Kaplan-Meier estimates of DFS 
are shown according to disease stage. Among patients 
with stage II disease, 5-year DFS rates were very close 
in the 2 groups (Fig. 2); but, for those with stage III dis-
ease, 5 year DFS for Group B was better than for Group 
A (Fig. 3).                                
Time After Surgery (Months)
Time After Surgery (Months)Time After Surgery (Months)
Fig. 1. Disease-free survival for the 58 patients in Group B (who 
underwent gastrectomies during 2003–2008; solid line) was better 
than that of the 82 patients in Group A (who underwent gastrecto-
mies during 1998–2002; dotted line), but not signifi cantly differ-
ent (P = 0.095). 
Fig. 3. Disease-free survival for the 50 patients in Group B with 
stage III (who underwent gastrectomies during 2003–2008; solid 
line) was better than that of the 26 patients in Group A with stage 
III (who underwent gastrectomies during 1998–2002; dotted line), 
but not signifi cantly different (P = 0.350). 
Fig. 2. Disease-free survival for the 32 patients in Group B with 
stage II (who underwent gastrectomies during 2003–2008; solid 
line) was better than that of the 32 patients in Group A with stage 
II (who underwent gastrectomies during 1998–2002; dotted line), 
but not signifi cantly different (P = 0.903).
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DISCUSSION
As ADJ has become more sophisticated, the survival of 
patients with operable advanced GC has improved. In 
the present study, we analyzed changes in outcome as 
standard treatments for advanced GC have changed. We 
found that DFS for patients treated between 2003 and 
2008 was longer than that of patients treated between 
1998 and 2002. The quality of surgery for advanced GC 
(as represented by the number of dissected lymph nodes) 
did not change between the 2 periods. The prognostic 
improvement was most conspicuous in patients with 
stage III disease who were treated with S-1 ADJ. 
 The UFT has been used as adjuvant drug for ad-
vanced GC for a long time in Japan. Even though our 
sample size was small, the effectiveness of UFT as ADJ 
for GC was confirmed.3 However, since S-1 has become 
widely used in this clinical context, the situation has 
changed completely. S-1 was developed as an oral anti-
cancer agent that combines tegafur (a prodrug of fluoro-
uracil) with 5-chloro-2,4-dihydropyrimidine and potas-
sium oxonate at a molar ratio of 1:0.4:1 (Taiho Pharma-
ceutical, Tokyo, Japan).7 The Adjuvant Chemotherapy 
Trial of S-1 for Gastric Cancer (ACTS-GC) confirmed 
that oral S-1 administration for 1 year significantly im-
proved DFS in patients with stage II–III GC after cura-
tive surgery.4 From 2007 on, oral S-1 administration for 
1 year has therefore been recognized as the standard 
postoperative ADJ for advanced GC in Japan,5 and has 
been widely used in that setting since 2002. 
 In this study, a small amount of cancer cells re-
mained after gastrectomy in stage II. S-1 and UFT were 
effective in killing the cancer cells in this stage. In stage 
III, S-1 was effective but UFT (serosa-negative, locally 
advanced) was not effective in killing cancer cells be-
cause a small amount of cancer cells remained. So, DFS 
for S-1 was better than that of UFT in stage III whereas 
it was close in stage II. 
 We had little data for our patients. In the ACTS-
GC trail, 5-year DFS rates for S-1 were 65.4%.8 Survival 
rates of S-1 ADJ in the present study were close to the 
ACTS-GC trail.
 No randomized study comparing UFT versus S-1 as 
ADJ for patients with stage II–III GC has been conduct-
ed in Japan. This study is limited by its small sample 
size, retrospective design and single-institution cohort. 
In our hospital, procedures for GC are performed by 
specialists in GC treatment. Although surgical quality 
was not changed, the prognosis of patients with stage III 
GC improved in more recently treated patients. These 
data indicate the usefulness of S-1 as ADJ for these pa-
tients.  
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